Matinas BioPharma (MTNB) Investor Presentation - Slideshow

MAT9001 - Potential Best-in-Class Omega-3 Drug - MAT9001 aims to target the multi-billion dollar market for severe hypertriglyceridemia (SHTG) [8, 25] - Head-to-head data showed MAT9001's superiority in triglyceride lowering and EPA levels compared to Vascepa® [8] - Approximately 3.5 to 4 million adults in the United States have severe hypertriglyceridemia (SHTG, ≥500 mg/dL) [28] - The ENHANCE-IT study, a head-to-head comparison of MAT9001 vs Vascepa®, is fully enrolled as of August 2020, with top-line data expected in Q1 2021 [14] - MAT9001 demonstrated a median triglyceride reduction of -33% versus -32.5% for Vascepa® in a head-to-head study [36] MAT2203 - Oral Amphotericin B for Invasive Fungal Infections - The global invasive fungal infection market is valued at approximately $6 billion in 2018 [65] - Global Amphotericin B sales were approximately $800 million in 2018 [65] - EnACT study is a Phase 2 study in HIV patients with Cryptococcal Meningitis [9, 73] LNC Platform - Matinas' LNC Platform enables flexible, safe, targeted delivery of potent medicines [10, 79] - The company has feasibility evaluations with three Big Pharma companies across multiple compounds [10] - $50M+ equity financing in January 2020 extends cash runway to early 2023 [16]